408 related articles for article (PubMed ID: 30658728)
1. Non-invasive diagnosis and biomarkers in alcohol-related liver disease.
Moreno C; Mueller S; Szabo G
J Hepatol; 2019 Feb; 70(2):273-283. PubMed ID: 30658728
[TBL] [Abstract][Full Text] [Related]
2. Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.
Stevenson M; Lloyd-Jones M; Morgan MY; Wong R
Health Technol Assess; 2012; 16(4):1-174. PubMed ID: 22333291
[TBL] [Abstract][Full Text] [Related]
3. Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease.
Lombardi R; Buzzetti E; Roccarina D; Tsochatzis EA
World J Gastroenterol; 2015 Oct; 21(39):11044-52. PubMed ID: 26494961
[TBL] [Abstract][Full Text] [Related]
4. Multiparametric magnetic resonance imaging/magnetic resonance elastography assesses progression and regression of steatosis, inflammation, and fibrosis in alcohol-associated liver disease.
Chen J; Martin-Mateos R; Li J; Yin Z; Chen J; Lu X; Glaser KJ; Mounajjed T; Yashiro H; Siegelman J; Winkelmann CT; Wang J; Ehman RL; Shah VH; Yin M
Alcohol Clin Exp Res; 2021 Oct; 45(10):2103-2117. PubMed ID: 34486129
[TBL] [Abstract][Full Text] [Related]
5. Transient elastography using Fibroscan is the most reliable noninvasive method for the diagnosis of advanced fibrosis and cirrhosis in alcoholic liver disease.
Fernandez M; Trépo E; Degré D; Gustot T; Verset L; Demetter P; Devière J; Adler M; Moreno C
Eur J Gastroenterol Hepatol; 2015 Sep; 27(9):1074-9. PubMed ID: 26011235
[TBL] [Abstract][Full Text] [Related]
6. Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement.
Karlas T; Petroff D; Sasso M; Fan JG; Mi YQ; de Lédinghen V; Kumar M; Lupsor-Platon M; Han KH; Cardoso AC; Ferraioli G; Chan WK; Wong VW; Myers RP; Chayama K; Friedrich-Rust M; Beaugrand M; Shen F; Hiriart JB; Sarin SK; Badea R; Lee HW; Marcellin P; Filice C; Mahadeva S; Wong GL; Crotty P; Masaki K; Bojunga J; Bedossa P; Keim V; Wiegand J
Aliment Pharmacol Ther; 2018 Apr; 47(7):989-1000. PubMed ID: 29446106
[TBL] [Abstract][Full Text] [Related]
7. Non-invasive diagnosis of alcoholic liver disease.
Mueller S; Seitz HK; Rausch V
World J Gastroenterol; 2014 Oct; 20(40):14626-41. PubMed ID: 25356026
[TBL] [Abstract][Full Text] [Related]
8. Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease.
Thiele M; Madsen BS; Hansen JF; Detlefsen S; Antonsen S; Krag A
Gastroenterology; 2018 Apr; 154(5):1369-1379. PubMed ID: 29317276
[TBL] [Abstract][Full Text] [Related]
9. Transient elastography alone and in combination with FibroTest
Voican CS; Louvet A; Trabut JB; Njiké-Nakseu M; Dharancy S; Sanchez A; Corouge M; Lamouri K; Lebrun A; Balian A; Prévot S; Lachgar M; Maitre S; Agostini H; Mathurin P; Perlemuter G; Naveau S
Liver Int; 2017 Nov; 37(11):1697-1705. PubMed ID: 28387018
[TBL] [Abstract][Full Text] [Related]
10. Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography.
Imajo K; Kessoku T; Honda Y; Tomeno W; Ogawa Y; Mawatari H; Fujita K; Yoneda M; Taguri M; Hyogo H; Sumida Y; Ono M; Eguchi Y; Inoue T; Yamanaka T; Wada K; Saito S; Nakajima A
Gastroenterology; 2016 Mar; 150(3):626-637.e7. PubMed ID: 26677985
[TBL] [Abstract][Full Text] [Related]
11. Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease using acoustic radiation force impulse elastography.
Zhang D; Li P; Chen M; Liu L; Liu Y; Zhao Y; Wang R
Abdom Imaging; 2015 Apr; 40(4):723-9. PubMed ID: 24811766
[TBL] [Abstract][Full Text] [Related]
12. Ultrasound Shear Wave Elastography for Liver Disease. A Critical Appraisal of the Many Actors on the Stage.
Piscaglia F; Salvatore V; Mulazzani L; Cantisani V; Schiavone C
Ultraschall Med; 2016 Feb; 37(1):1-5. PubMed ID: 26871407
[TBL] [Abstract][Full Text] [Related]
13. Prognostic performance of 7 biomarkers compared to liver biopsy in early alcohol-related liver disease.
Rasmussen DN; Thiele M; Johansen S; Kjærgaard M; Lindvig KP; Israelsen M; Antonsen S; Detlefsen S; Krag A; ;
J Hepatol; 2021 Nov; 75(5):1017-1025. PubMed ID: 34118335
[TBL] [Abstract][Full Text] [Related]
14. Transient Elastography and Controlled Attenuation Parameter for Diagnosing Liver Fibrosis and Steatosis in Ontario: An Economic Analysis.
Thavorn K; Coyle D
Ont Health Technol Assess Ser; 2015; 15(19):1-58. PubMed ID: 26664666
[TBL] [Abstract][Full Text] [Related]
15. Optimization of hepatitis B cirrhosis detection by stepwise application of transient elastography and routine biomarkers.
Liang XE; Zhong C; Huang L; Yang S; Zhu Y; Chen Y; Hou J
J Gastroenterol Hepatol; 2017 Feb; 32(2):459-465. PubMed ID: 27346683
[TBL] [Abstract][Full Text] [Related]
16. Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis.
Poynard T; Deckmyn O; Peta V; Paradis V; Gautier JF; Brzustowski A; Bedossa P; Castera L; Pol S; Valla D;
Aliment Pharmacol Ther; 2023 Nov; 58(9):888-902. PubMed ID: 37642160
[TBL] [Abstract][Full Text] [Related]
17. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.
de Lédinghen V; Vergniol J; Foucher J; Merrouche W; le Bail B
Liver Int; 2012 Jul; 32(6):911-8. PubMed ID: 22672642
[TBL] [Abstract][Full Text] [Related]
18. The role of elastography for liver fibrosis screening in alcoholic liver disease.
Foncea CG; Moga TV; Sporea I; Popa A; Sirli R; Bende F; Popescu A; Fofiu R
Med Ultrason; 2022 Dec; 24(4):406-413. PubMed ID: 36546434
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Non-invasive tests are enough.
Castera L
Liver Int; 2018 Feb; 38 Suppl 1():67-70. PubMed ID: 29427494
[TBL] [Abstract][Full Text] [Related]
20. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
